Loading...
•
Sep 30, 2024
Arcellx Q3 2024 Earnings Report
Arcellx reported financial results and business highlights for Q3 2024.
Key Takeaways
Arcellx reported collaboration revenue of $26.0 million for the third quarter of 2024, an increase of $11.0 million compared to the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $676.7 million as of September 30, 2024, which is expected to fund operations into 2027. Net losses for the quarter were $25.9 million.
ASH abstracts for Phase 1 and iMMagine-1 studies of anito-cel in relapsed/refractory multiple myeloma showed durability and manageable safety.
Phase 1 study of anito-cel demonstrated a 30.2-month median progression-free survival with a median follow-up of 38.1 months.
Preliminary results from the iMMagine-1 Phase 2 study showed a 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months.
First patients dosed in iMMagine-3 study, manufactured by Kite, with turnaround time in line with Kite’s commercial products.
Arcellx
Arcellx
Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.